Anika Therapeutics (ANIK) Receiving Somewhat Positive News Coverage, Study Shows

Media stories about Anika Therapeutics (NASDAQ:ANIK) have been trending somewhat positive on Monday, according to Accern Sentiment Analysis. The research firm identifies positive and negative media coverage by analyzing more than 20 million blog and news sources. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Anika Therapeutics earned a coverage optimism score of 0.23 on Accern’s scale. Accern also gave media headlines about the biotechnology company an impact score of 46.2553820845101 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the next several days.

Anika Therapeutics (ANIK) opened at $59.03 on Monday. The company has a market capitalization of $865.48, a price-to-earnings ratio of 27.71, a price-to-earnings-growth ratio of 3.58 and a beta of 1.44. Anika Therapeutics has a 12-month low of $41.64 and a 12-month high of $60.29.

Anika Therapeutics (NASDAQ:ANIK) last announced its quarterly earnings data on Wednesday, October 25th. The biotechnology company reported $0.46 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.41 by $0.05. The company had revenue of $27.18 million for the quarter, compared to the consensus estimate of $27.44 million. Anika Therapeutics had a return on equity of 13.40% and a net margin of 28.23%. Anika Therapeutics’s quarterly revenue was up 5.4% on a year-over-year basis. During the same quarter in the prior year, the company posted $0.59 EPS. equities analysts predict that Anika Therapeutics will post 1.9 earnings per share for the current year.

Several research firms recently weighed in on ANIK. BidaskClub upgraded Anika Therapeutics from a “sell” rating to a “hold” rating in a report on Wednesday, December 27th. Barrington Research increased their price target on Anika Therapeutics from $53.00 to $57.00 and gave the company an “outperform” rating in a report on Friday, October 27th.

In other Anika Therapeutics news, insider Richard Hague sold 5,250 shares of the company’s stock in a transaction on Thursday, November 30th. The stock was sold at an average price of $54.48, for a total value of $286,020.00. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Corporate insiders own 6.57% of the company’s stock.

TRADEMARK VIOLATION NOTICE: This story was reported by Week Herald and is the sole property of of Week Herald. If you are reading this story on another site, it was illegally stolen and reposted in violation of US & international copyright and trademark legislation. The original version of this story can be read at

About Anika Therapeutics

Anika Therapeutics, Inc is an orthopedic medicines company. The Company is engaged in developing, manufacturing and commercializing products based on its hyaluronic acid (HA) technology. The Company’s orthopedic medicine portfolio includes ORTHOVISC, MONOVISC, and CINGAL, which alleviate pain and restore joint function by replenishing depleted HA, and HYALOFAST, a solid HA-based scaffold to aid cartilage repair and regeneration.

Insider Buying and Selling by Quarter for Anika Therapeutics (NASDAQ:ANIK)

Receive News & Ratings for Anika Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anika Therapeutics and related companies with's FREE daily email newsletter.

Leave a Reply